These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 35021170)

  • 1. Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective.
    AlSahow A; Al-Muhaiteeb A; Nawar H; AlHelal B; AlYousef A; Abdallah E; AbuShall A; Elmekawi S; Meshal B; AlQallaf A; AlRajab H
    Med Princ Pract; 2022; 31(2):133-141. PubMed ID: 35021170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab use in adult glomerulopathies and its rationale.
    Santos JE; Fiel D; Santos R; Vicente R; Aguiar R; Santos I; Amoedo M; Pires C
    J Bras Nefrol; 2020 Mar; 42(1):77-93. PubMed ID: 31904761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab in glomerular diseases: a case series and narrative review.
    Duarte I; Oliveira J; Outerelo C; Godinho I; Pereira M; Fernandes P; Jorge S; Gameiro J
    J Bras Nefrol; 2022; 44(2):187-195. PubMed ID: 34874051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.
    Ma X; Fang L; Sheng L; Zhou X; Bai S; Zang X; Wang Y; Li M; Lv Z; Zhong Q; Yang X; Wang Y; Hu Y; Yan D; Shi Y; Chen H; Li J; Tao M; Zhuang S; Wang Y; Liu N
    Ren Fail; 2023 Dec; 45(1):2237124. PubMed ID: 37482915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.
    Bomback AS; Canetta PA; Beck LH; Ayalon R; Radhakrishnan J; Appel GB
    Am J Nephrol; 2012; 36(1):58-67. PubMed ID: 22722778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.
    Mariani LH; Bomback AS; Canetta PA; Flessner MF; Helmuth M; Hladunewich MA; Hogan JJ; Kiryluk K; Nachman PH; Nast CC; Rheault MN; Rizk DV; Trachtman H; Wenderfer SE; Bowers C; Hill-Callahan P; Marasa M; Poulton CJ; Revell A; Vento S; Barisoni L; Cattran D; D'Agati V; Jennette JC; Klein JB; Laurin LP; Twombley K; Falk RJ; Gharavi AG; Gillespie BW; Gipson DS; Greenbaum LA; Holzman LB; Kretzler M; Robinson B; Smoyer WE; Guay-Woodford LM;
    Am J Kidney Dis; 2019 Feb; 73(2):218-229. PubMed ID: 30420158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
    Aqeel F; Xu L; Salas A; Wen Y; Eid SM; Geetha D
    Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
    Hansrivijit P; Cheungpasitporn W; Thongprayoon C; Ghahramani N
    BMC Nephrol; 2020 Apr; 21(1):134. PubMed ID: 32293308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study.
    Wang CS; Glenn DA; Helmuth M; Smith AR; Bomback AS; Canetta PA; Coppock GM; Khalid M; Tuttle KR; Bou-Matar R; Greenbaum LA; Robinson BM; Holzman LB; Smoyer WE; Rheault MN; Gipson D; Mariani LH;
    Am J Kidney Dis; 2024 Jan; 83(1):37-46. PubMed ID: 37657635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
    Lin L; Wang W; Wu Y; Xie J; Li X; Pan X; Zhang W; Xu J; Cai Y; Ren H; Chen N
    Drug Des Devel Ther; 2021; 15():1945-1953. PubMed ID: 34007154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
    Rovin BH; Adler SG; Barratt J; Bridoux F; Burdge KA; Chan TM; Cook HT; Fervenza FC; Gibson KL; Glassock RJ; Jayne DRW; Jha V; Liew A; Liu ZH; Mejía-Vilet JM; Nester CM; Radhakrishnan J; Rave EM; Reich HN; Ronco P; Sanders JF; Sethi S; Suzuki Y; Tang SCW; Tesar V; Vivarelli M; Wetzels JFM; Lytvyn L; Craig JC; Tunnicliffe DJ; Howell M; Tonelli MA; Cheung M; Earley A; Floege J
    Kidney Int; 2021 Oct; 100(4):753-779. PubMed ID: 34556300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
    Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
    Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
    Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
    J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glomerulonephritis Histopathological Pattern Change.
    AlYousef A; AlSahow A; AlHelal B; Alqallaf A; Abdallah E; Abdellatif M; Nawar H; Elmahalawy R
    BMC Nephrol; 2020 May; 21(1):186. PubMed ID: 32423387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Instructions and implementations for percutaneous renal biopsy. Guidelines for the therapy of glomerular nephropaties].
    Cagnoli L;
    G Ital Nefrol; 2003; 20 Suppl 24():S3-47. PubMed ID: 14666502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab.
    Yoshida S; Hanai S; Nakagomi D; Kobayashi K; Takahashi K; Furuya F
    Intern Med; 2021 Jan; 60(1):145-150. PubMed ID: 32830174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art].
    Cravedi P
    G Ital Nefrol; 2012; 29(3):274-82; discussion 292. PubMed ID: 22718450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
    Kronbichler A; Kerschbaum J; Fernandez-Fresnedo G; Hoxha E; Kurschat CE; Busch M; Bruchfeld A; Mayer G; Rudnicki M
    Am J Nephrol; 2014; 39(4):322-30. PubMed ID: 24751753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.